Shionogi Continues Rare Disease Expansion With Planned Acquisition Of Intrabio Inc
05/10/2026 07:05
BRIEF-Shionogi & Co., Ltd.- Shionogi Continues Rare Disease Expansion With Planned Acquisition Of Intrabio Inc Oct 5 (Reuters) - Shionogi & Co., Ltd. 4507.T:
SHIONOGI & CO., LTD.: SHIONOGI CONTINUES RARE DISEASE EXPANSION WITH PLANNED ACQUISITION OF INTRABIO INC
SHIONOGI & CO LTD: SHIONOGI INC. WILL ACQUIRE ALL OUTSTANDING SHARES OF INTRABIO FOR AN UPFRONT CONSIDERATION OF USD 2.0 BILLION PAYABLE TO INTRABIO SHAREHOLDERS
SHIONOGI & CO LTD: IMPACT OF PROPOSED TRANSACTION ON SHIONOGI'S CONSOLIDATED FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 2027 IS CURRENTLY UNDER REVIEW
Source text: ID:nTSve8550b
Further company coverage: 4507.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Shionogi & Co.
See all newsShionogi Continues Rare Disease Expansion With Planned Acquisition Of Intrabio Inc
Covgoze For Intramuscular Injection (Jn.1-Adapted), Recombinant Protein Covid-19 Vaccine, Receives Partial Change Approval In Japan
Notice Regarding Approval Of An Additional Dosage And Administration Of Vtama Cream For Pediatric Atopic Dermatitis (Under Age12) In Japan
Announces U.S. Government Procurement Of Fetroja (Cefiderocol) Through Barda's Project Bioshield
Media: Shionogi CEO pursues drug deals, mulls expanded US production - Bloomberg News